ESC Congress 2016 - i

ESC CONGRESS 2016 IN REVIEW Dear Colleagues, We are delighted to share these peer-reviewed highlights from the European Society of Cardiology (ESC) Congress 2016 held in Rome, Italy. This was a really exciting congress! A record number of attendees, more than 33,000 joined us in Rome, a reflection of the calibre of scientific content submitted to the congress. His Holiness Pope Francis honoured ESC Congress 2016 with a special visit in recognition of the significant efforts by the ESC and medical professionals worldwide to advance prevention, diagnosis and treatment of heart disease. This year's congress spotlight focused on the importance of the Heart Team and a multidisciplinary approach to managing patients with cardiovascular disease. Exciting new tracks this year include surgery, stroke, and e-cardiology. Over the 5 days of the congress, 26 Hot Lines, 25 Clinical Trial Updates, 23 Registry presentations, 4 new ESC Clinical Practice Guidelines, a position paper on Cardio-Oncology, and 4594 abstracts were presented. ESC Congress 365 is an enduring educational product that provides the videos, slides, abstracts, and reports of ESC Congress presentations through the ESC website. We view this as an important resource for physicians worldwide, and we aim for this resource to create interactive discussions among colleagues about what innovations are applicable in their particular settings. The scope and quality of the abstracts presented continue to make ESC Congress an exciting and innovative forum in which advances in research can be translated into practical applications for clinicians. The articles selected for this issue of ESC Congress 2016 in Review, the official highlights report for ESC Congress 2016, represent the most newsworthy and cutting-edge items of relevance to a broad array of practitioners. Some of the studies and the new ESC Clinical Practice Guidelines presented live at ESC Congress 2016 and in the pages of ESC Congress 2016 in Review will influence clinical practice and will allow us to better understand how to manage important conditions and how to devise new therapies. Results from the ODYSSEY-ESCAPE trial showed that the PCSK9 inhibitor, alirocumab, can significantly reduce or even eliminate the need for expensive and time-consuming apheresis treatments in patients who have heterozygous familial hypercholesterolemia. By the end of the study, patients treated with alirocumab had a 75% greater reduction in apheresis compared with those on placebo. The REVERSE II trial prospectively validated the HERDOO2 rule (named for the 4 risk factors that must be considered in determining a patient's risk of venous thromboembolism [VTE]), making it the only currently validated clinical decision rule to assist clinicians, patients and policy makers to decide who can discontinue anticoagulants after unprovoked VTE; an important finding since current consensus guidelines suggest anticoagulants should be continued indefinitely in all patients with unprovoked VTE and non-high bleeding risk. The PRAGUE-18 study, a head-to-head trial of prasugrel and ticagrelor in patients with acute STEMI treated with PCI, found them to be equally safe and effective in preventing the primary composite end point of death, reinfarction, urgent target vessel revascularization, stroke, bleeding requiring transfusion, or prolonged hospitalization at 7 days. In addition to learning about the results of top late-breaking clinical trials in this dedicated highlights report, you will also find new information in selected, challenging areas of cardiovascular medicine. We hope that the articles and practical perspectives contained in the pages of this edition of ESC Congress 2016 in Review will be useful in your clinical practice. To access ESC Congress content (videos, slides, abstracts, and reports) all year long, visit us online at www.escardio.org/365. We wish you all a successful year and look forward to seeing you in Barcelona for ESC Congress 2017. For more information, please visit www.escardio.org/ESC2017. Geneviève Derumeaux, MD, PhD, FESC ESC Congress Programme Committee Chair 2014-2016 Official Peer-Reviewed Highlights From ESC Congress 2016 i http://www.escardio.org/365 http://www.escardio.org/ESC2017

Table of Contents for the Digital Edition of ESC Congress 2016